Trevi Therapeutics

New Haven’s Trevi Therapeutics plans $150M stock offering to fund late-stage drug trials

New Haven-based Trevi Therapeutics Inc. disclosed it is seeking to raise $150 million through a public stock offering to support development of its drug candidate for chronic cough, according to a regulatory filing.

🔒New Haven biotech Trevi Therapeutics builds billion-dollar valuation around lone late-stage cough drug

New Haven-based Trevi Therapeutics has raised more than $250 million to develop Haduvio, the only drug in development for chronic cough, with the company preparing Phase 3 trials targeting patients with idiopathic pulmonary fibrosis who cough thousands of times daily.

New Haven biotech names new CFO

New Haven clinical-stage drug developer Trevi Therapeutics Inc. announced that David Hastings has been hired as its new CFO.

🔒CFO at CT bioscience company to step down

New Haven-based Trevi Therapeutics Inc. disclosed Wednesday that its chief financial officer will be leaving her post on Friday.
- Advertisement -
Get our email newsletters

Stay up-to-date on the companies, people and issues that impact businesses in Hartford and beyond.

Sign Up Now
ADVERTISEMENT

Latest Stories

More Business News

Movers & Shakers

More Movers & Shakers | Submit an Announcement
ADVERTISEMENT

Thought Leadership

More Thought Leadership

Career Opportunities

Chief Financial Officer

Hoffman Auto Group
,
East Hartford, CT
$250,000.00 - $400,000.00

Project Development/Sales

Borghesi Building & Engineering, Co., Inc.
,
Torrington, CT
Base salary plus commission. Range $70,000-$170,000 per year.
More Jobs | Submit a Job

Upcoming Events

View Calendar
More Events | Submit an Event